Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Musculoskeletal Tumors Clear all
Terminated Phase 1 Interventional

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530
View directory record Official record
Conditions
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions
PLX7486 TsOH
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 5, 2026, 5:48 AM EDT
Recruiting No phase listed Observational

Post-contracture Release Radiation for Dupuytren's Disease

NCT04122313
View directory record Official record
Conditions
Dupuytren's Disease, Dupuytren Contracture, Dupuytren Disease of Palm and Finger, Dupuytren Disease of Finger, Dupuytrens Contracture of Both Hands, Dupuytren's Disease of Palm of Right Hand, Dupuytren's Disease of Palm of Left Hand, Dupuytren Contracture of Right Palm, Dupuytren Contracture of Left Palm, Dupuytren's Contracture Left, Dupuytren's Contracture Right
Interventions
Evaluation of Dupuytren's Disease Treatment
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations

NCT02461446
View directory record Official record
Conditions
PTEN, ASD, Autism, Macrocephaly, PTEN Hamartoma Tumor Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Months and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

NCT00580788
View directory record Official record
Conditions
Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
Interventions
PTHrP (1-36)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Oct 5, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

NCT06160752
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Completed No phase listed Observational

Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System

NCT00726128
View directory record Official record
Conditions
Trauma, Tumor, Pseudarthrosis, Scoliosis, Degenerative Disc Disease
Interventions
VueLock™ Anterior Cervical Plate
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
Not listed
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
4
States / cities
Palo Alto, California • San Diego, California • Avon, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO

NCT02819011
View directory record Official record
Conditions
Accidental Falls, Fall Due to Loss of Equilibrium, High Risk of Falls Due to Mobility Limitation, Diabetes, Arthritis, Cancer, Peripheral Arterial Disease, Parkinson's Disease, End Stage Renal Failure on Dialysis
Interventions
MBB AFO, Control
Device · Other
Lead sponsor
Bijan Najafi, PhD
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 5, 2026, 5:48 AM EDT
Withdrawn Early Phase 1 Interventional

Gemcitabine With Ascorbate Including Adolescents

NCT04877587
View directory record Official record
Conditions
Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Soft-tissue Sarcoma, Unresectable Bone Sarcoma
Interventions
Ascorbate, Gemcitabine
Drug
Lead sponsor
David Dickens
Other
Eligibility
13 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 5, 2026, 5:48 AM EDT
Terminated Phase 4 Interventional Results available

Non-cancer Pain and Cognitive Impairment: A Disabling Relationship

NCT01264965
View directory record Official record
Conditions
Arthritis, Pain, Cognitive Impairment
Interventions
long acting oxycodone, extra strength acetaminophen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
65 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Auricular Point Acupressure to Self-Manage Chronic Pain or Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors: Effectiveness and Scientific Underpinnings

NCT03697200
View directory record Official record
Conditions
Aromatase Inhibitor, Musculoskeletal Symptoms, Postmenopausal Breast Cancer Survivors
Interventions
APA, Sham APA control, Education control
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 5, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

NCT05101798
View directory record Official record
Conditions
Neoplasm, Skull Base Neoplasm
Interventions
5-Aminolevulinic acid Hydrochloride
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Not applicable Interventional Results available

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

NCT00261807
View directory record Official record
Conditions
Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene
Interventions
Daptomycin 6mg/kg/day
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery

NCT04233385
View directory record Official record
Conditions
Breast Cancer, Mastectomy; Lymphedema, Pain, Shoulder, Mobility Limitation
Interventions
Myofascial Massage, Light Touch
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 5, 2026, 5:48 AM EDT
Active, not recruiting Phase 3 Interventional

Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia

NCT05703178
View directory record Official record
Conditions
Breast Cancer, Arthralgia, Pain, Chronic
Interventions
Online Pain Coping Skills Training, Education
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 5, 2026, 5:48 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

NCT05898074
View directory record Official record
Conditions
Skull Base Neoplasms, Cerebrospinal Fluid Leakage, Nasal; Hypertrophy, Mucous Membrane (Septum)
Interventions
Non-Absorbable Packing (Silastic Splint), PuraGel (RADA16) Hydrogel
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex

NCT01450397
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
XIAFLEX
Biological
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
35 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Oct 5, 2026, 5:48 AM EDT
Completed No phase listed Observational

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

NCT06253897
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Not applicable Interventional Results available

Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial

NCT02083861
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Sam Ultrasonic Diathermy Device
Device
Lead sponsor
ZetrOZ, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Dryden, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)

NCT00602420
View directory record Official record
Conditions
Musculoskeletal Complications, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naproxen, placebo
Drug · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
16
States / cities
Honolulu, Hawaii • Decatur, Illinois • Evanston, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 5, 2026, 5:48 AM EDT
Not yet recruiting Phase 2 Interventional

Pilot Study of Hydroxychloroquine for the Treatment of AIMSS

NCT07825454
View directory record Official record
Conditions
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 5, 2026, 5:48 AM EDT
Terminated Not applicable Interventional

Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma

NCT01882231
View directory record Official record
Conditions
Osteosarcoma, Paget's Disease, Ewing Sarcoma
Interventions
DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
13 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Not applicable Interventional Results available

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

NCT01028352
View directory record Official record
Conditions
Breast Cancer
Interventions
Duloxetine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Oct 5, 2026, 5:48 AM EDT
Completed Phase 4 Interventional Results available

Retreatment of Recurrent Dupuytren's Contractures

NCT01498640
View directory record Official record
Conditions
Dupuytren's Disease
Interventions
Collagenase clostridium histolyticum
Biological
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Phoenix, Arizona • Rockford, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 5, 2026, 5:48 AM EDT